## Management of 5-FU Toxicity: Diarrhea and Mucositis ### Recognition of Severe 5-FU Toxicity **Key Point:** Grade 3 diarrhea (≥7 stools/day) and grade 3 mucositis in the setting of 5-FU therapy constitute **dose-limiting toxicity** that requires immediate intervention. These are not minor side effects but rather indicators of significant systemic exposure and risk of life-threatening complications (dehydration, sepsis, malnutrition). ### Pathophysiology of 5-FU Toxicity 5-FU is an antimetabolite that inhibits thymidylate synthase and is incorporated into RNA/DNA. Gastrointestinal epithelium (with high cell turnover) is particularly vulnerable. Toxicity is dose- and schedule-dependent; continuous infusion regimens carry higher GI toxicity risk than bolus dosing. ### Mechanism of Interindividual Variability **High-Yield:** **Dihydropyrimidine dehydrogenase (DPD) deficiency** is a pharmacogenetic trait present in ~3–5% of the population that causes severe, sometimes fatal 5-FU toxicity. DPD catalyzes the catabolism of 5-FU; deficiency leads to drug accumulation. Screening for DPD deficiency (via genotyping or phenotyping) before 5-FU initiation is now recommended in many centers; patients with deficiency require dose reduction (50–75% of standard dose) or alternative agents. ### Management Algorithm ```mermaid flowchart TD A[5-FU therapy initiated]:::outcome --> B{Grade 3+ diarrhea or mucositis?}:::decision B -->|Yes| C[HOLD 5-FU immediately]:::action C --> D[IV hydration, electrolyte repletion]:::action D --> E[Prescribe octreotide 100–150 μg SC TID for diarrhea]:::action E --> F[Assess for DPD deficiency]:::action F --> G{DPD deficiency present?}:::decision G -->|Yes| H[Reduce dose 50–75% for next cycle or use alternative]:::action G -->|No| I[Reduce dose 20–25% for next cycle]:::action B -->|No| J[Continue standard dosing]:::action ``` ### Why Holding 5-FU Is Critical **Clinical Pearl:** Continuing 5-FU in the face of grade 3 GI toxicity risks progression to grade 4 toxicity (life-threatening diarrhea with dehydration, sepsis, acute kidney injury). The drug should be held, supportive care initiated, and the cause of toxicity investigated before re-challenging. ### Supportive Care Components | Intervention | Rationale | |---|---| | **IV hydration** | Correct dehydration from diarrhea; maintain renal perfusion | | **Octreotide 100–150 μg SC TID** | Somatostatin analog; reduces secretory diarrhea by 40–60% | | **Loperamide** | **Avoid in infectious diarrhea or severe cases** — risk of toxic megacolon; safe only for mild diarrhea | | **Antimotility agents** | Not first-line in chemotherapy-induced diarrhea; reserve for grade 1–2 | **Warning:** Loperamide alone, without octreotide and IV hydration, is insufficient for grade 3 diarrhea and may worsen outcomes by trapping toxins in the bowel. ### Dose Adjustment for Subsequent Cycles - **No DPD deficiency:** Reduce 5-FU dose by 20–25% for the next cycle - **DPD deficiency identified:** Reduce dose by 50–75% OR switch to capecitabine (oral 5-FU prodrug; also contraindicated in DPD deficiency) or alternative chemotherapy (irinotecan, oxaliplatin monotherapy) **Mnemonic:** **DPD = Dose Problem Deficiency** — if DPD is deficient, the patient cannot metabolize 5-FU; dose must be drastically reduced. ### Why TPN Is Not First-Line TPN is reserved for prolonged inability to eat (>7–10 days) or severe malnutrition. In this case, the diarrhea is acute and reversible with octreotide and hydration; TPN delays chemotherapy unnecessarily and carries infection risk. [cite:Harrison 21e Ch 89; KD Tripathi 8e Ch 65]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.